Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study

被引：0
|
作者：
Mototsugu Shimokawa
Kaname Nosaki
Takashi Seto
Kadoaki Ohashi
Masahiro Morise
Hidehito Horinouchi
Jun Sakakibara
Haruyasu Murakami
Seiji Yano
Miyako Satouchi
Shingo Matsumoto
Koichi Goto
Kiyotaka Yoh
机构：
[1] National Hospital Organization Kyushu Cancer Center,Cancer Biostatistics Laboratory, Clinical Research Institute
[2] Yamaguchi University Graduate School of Medicine,Department of Biostatistics
[3] National Hospital Organization Kyushu Cancer Center,Department of Thoracic Oncology
[4] National Cancer Center Hospital East,Department of Thoracic Oncology
[5] Okayama University Hospital,Department of Allergy and Respiratory Medicine
[6] Nagoya University Graduate School of Medicine,Department of Respiratory Medicine
[7] National Cancer Center Hospital,Department of Thoracic Oncology
[8] Hokkaido University Hospital,First Department of Medicine
[9] Shizuoka Cancer Center,Division of Thoracic Oncology
[10] Kanazawa University,Division of Medical Oncology, Cancer Research Institute
[11] Hyogo Cancer Center,Department of Thoracic Oncology
来源：
Trials | / 21卷
关键词：
Non-small cell lung cancer; Crizotinib; MET gene alteration; RT-PCR assay; Next-generation sequencing;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
    Shimokawa, Mototsugu
    Nosaki, Kaname
    Seto, Takashi
    Ohashi, Kadoaki
    Morise, Masahiro
    Horinouchi, Hidehito
    Sakakibara, Jun
    Murakami, Haruyasu
    Yano, Seiji
    Satouchi, Miyako
    Matsumoto, Shingo
    Goto, Koichi
    Yoh, Kiyotaka
    TRIALS, 2020, 21 (01)
  • [2] Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
    Shimokawa, M.
    Nosaki, K.
    Seto, T.
    Ohashi, K.
    Morise, M.
    Fujiwara, Y.
    Sakakibara, J.
    Murakami, H.
    Yano, S.
    Satouchi, M.
    Matsumoto, S.
    Goto, K.
    Yoh, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study
    Nosaki, Kaname
    Yoh, Kiyotaka
    Toyozawa, Ryo
    Horinouchi, Hidehito
    Morise, Masahiro
    Ohashi, Kadoaki
    Murakami, Haruyasu
    Satouchi, Miyako
    Sakakibara-Konishi, Jun
    Yano, Seiji
    Okumura, Fumihiko
    Matsumoto, Shingo
    Shimokawa, Mototsugu
    Seto, Takashi
    Goto, Koichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (08) : 1142 - 1151
  • [4] Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: Co-MET study
    Toyozawa, Ryo
    Nosaki, Kaname
    Shimokawa, Mototugu
    Horinouchi, Hidehito
    Morise, Masahiro
    Ohashi, Kadoaki
    Murakami, Haruyasu
    Satouchi, Miyako
    Sakakibara, Jun
    Yano, Seiji
    Matsumoto, Shingo
    Goto, Koichi
    Seto, Takashi
    Yoh, Kiyotaka
    ANNALS OF ONCOLOGY, 2022, 33 : S476 - S476
  • [5] A multicenter, open-label, phase IIIB trial of erlotinib in patients with advanced non-small cell lung cancer
    Hainsworth, J
    Spigel, D
    O'Neill, V
    Klencke, B
    LUNG CANCER, 2005, 49 : S246 - S247
  • [6] A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study
    Paik, P.
    Cortot, A.
    Felip, E.
    Sakai, H.
    Mazieres, J.
    Horn, L.
    Griesinger, F.
    Bruns, R.
    Scheele, J.
    Straub, J.
    Veillon, R.
    ANNALS OF ONCOLOGY, 2019, 30 : 66 - 66
  • [7] Phase II trial of the c-Met inhibitor tepotinib in patients with advanced non-small cell lung cancer harboring MET exon 14-skipping mutations
    Felip, Enriqueta
    Veillon, Remi
    Viteri, Santiago
    Scheele, Jurgen
    Bruns, Rolf
    Paik, Paul K.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [8] A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease
    Hanibuchi, Masaki
    Kakiuchi, Soji
    Atagi, Shinji
    Ogushi, Fumitaka
    Shimizu, Eiji
    Haku, Takashi
    Toyoda, Yuko
    Azuma, Masahiko
    Kondo, Mayo
    Kawano, Hiroshi
    Otsuka, Kenji
    Sakaguchi, Satoshi
    Nokihara, Hiroshi
    Goto, Hisatsugu
    Nishioka, Yasuhiko
    LUNG CANCER, 2018, 125 : 93 - 99
  • [9] A Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease
    Hanibuchi, M.
    Kakiuchi, S.
    Atagi, S.
    Ogushi, F.
    Shimizu, E.
    Haku, T.
    Toyoda, Y.
    Azuma, M.
    Kondo, M.
    Kawano, H.
    Otsuka, K.
    Sakaguchi, S.
    Nokihara, H.
    Goto, H.
    Nishioka, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S472 - S472
  • [10] ERLOTINIB IN PROGRESSIVE PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II OPEN-LABEL TRIAL
    Piantedosi, Francovito
    Vitiello, Fabiana
    Spina, Sergio
    Zinno, Luigia
    D'Agostino, Diego
    Caputo, Francesca
    Gilli, Marina
    Hengeller, Mario
    Iacobelli, Simona
    Casale, Beniamino
    Caputi, Mario
    Marsico, Serafino A.
    Bianco, Andrea
    ANNALS OF ONCOLOGY, 2009, 20
12345